EDSA has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
EDSA has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. Edesa Biotech's Revenue for the three months ended in Mar. 2024 was $0.00 Mil. Edesa Biotech's average Accounts Receivable for the three months ended in Mar. 2024 was $0.93 Mil.
The historical data trend for Edesa Biotech's Receivables Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Edesa Biotech Annual Data | |||||||||||||||||||||
Trend | Aug14 | Sep15 | Sep16 | Sep17 | Sep18 | Sep19 | Sep20 | Sep21 | Sep22 | Sep23 | |||||||||||
Receivables Turnover | Get a 7-Day Free Trial | 3.19 | 2.16 | - | - | - |
Edesa Biotech Quarterly Data | ||||||||||||||||||||
Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | |
Receivables Turnover | Get a 7-Day Free Trial | - | - | - | - | - |
For the Biotechnology subindustry, Edesa Biotech's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Edesa Biotech's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where Edesa Biotech's Receivables Turnover falls into.
Receivables Turnover measures the number of times a company collects its average accounts receivable balance.
Edesa Biotech's Receivables Turnover for the fiscal year that ended in Sep. 2023 is calculated as
Receivables Turnover (A: Sep. 2023 ) | |||||||
= | Revenue | / | Average Total Inventories | ||||
= | Revenue (A: Sep. 2023 ) | / ( | (Accounts Receivable (A: Sep. 2022 ) | + | Accounts Receivable (A: Sep. 2023 )) | / | count ) |
= | 0 | / ( | (1.255 | + | 0.627) | / | 2 ) |
= | 0 | / | 0.941 | ||||
= | N/A |
Edesa Biotech's Receivables Turnover for the quarter that ended in Mar. 2024 is calculated as
Receivables Turnover (Q: Mar. 2024 ) | |||||||
= | Revenue | / | Average Total Inventories | ||||
= | Revenue (Q: Mar. 2024 ) | / ( | (Accounts Receivable (Q: Dec. 2023 ) | + | Accounts Receivable (Q: Mar. 2024 )) | / | count ) |
= | 0 | / ( | (0.744 | + | 1.112) | / | 2 ) |
= | 0 | / | 0.928 | ||||
= | N/A |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Edesa Biotech (NAS:EDSA) Receivables Turnover Explanation
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
Thank you for viewing the detailed overview of Edesa Biotech's Receivables Turnover provided by GuruFocus.com. Please click on the following links to see related term pages.
Stephen Lemieux | officer: Chief Financial Officer | 100 SPY COURT, C/O EDESA BIOTECH, INC., MARKHAM A6 L3R 5H6 |
Joan Chypyha | director | 100 SPY COURT, MARKHAM A6 L3R 5H6 |
Patrick Marshall | director | 100 SPY COURT, MARKHAM A6 L3R 5H6 |
Van Der Velden Peter | director, 10 percent owner | C/O EDESA BIOTECH INC., 100 SPY COURT, MARKHAM A6 L3R 5H6 |
Michael J Brooks | officer: President | C/O EDESA BIOTECH INC., 100 SPY COURT, MARKHAM A6 L3R 5H6 |
Pardeep Nijhawan | director, 10 percent owner, officer: Chief Executive Officer | C/O EDESA BIOTECH INC., 100 SPY COURT, MARKHAM A6 L3R 5H6 |
Jennifer M Chao | director | 7 PURITAN WOODS ROAD, RYE NY 10580 |
Frank R. Oakes | director, officer: President, CEO, & Director | C/O STELLAR BIOTECHNOLOGIES, INC., 332 EAST SCOTT STREET, PORT HUENEME CA 93041 |
Sean Arthur Macdonald | director | C/O EDESA BIOTECH INC., 100 SPY COURT, MARKHAM A6 L3R 5H6 |
Lorin K Johnson | director | 3600 W BAYSHORE ROAD SUITE 205, PALO ALTO CA 94303 |
Pardeep Nijhawan Medicine Professional Corp | 10 percent owner | C/O EDESA BIOTECH INC., 100 SPY COURT, MARKHAM A6 L3R 5H6 |
Paul William Pay | director | C/O EDESA BIOTECH INC., 100 SPY COURT, MARKHAM A6 L3R 5H6 |
Carlo Sistilli | director | C/O EDESA BIOTECH INC., 100 SPY COURT, MARKHAM A6 L3R 5H6 |
Lumira Capital Investment Management Inc. | 10 percent owner | 141 ADELAIDE STREET WEST, SUITE 770, TORONTO A6 M5H 3L5 |
Daniel E. Morse | director | C/O STELLAR BIOTECHNOLOGIES, INC., 332 EAST SCOTT STREET, PORT HUENEME CA 93041 |
From GuruFocus
By ACCESSWIRE • 12-16-2023
By ACCESSWIRE ACCESSWIRE • 03-24-2023
By ACCESSWIRE ACCESSWIRE • 02-01-2023
By ACCESSWIRE ACCESSWIRE • 03-29-2022
By ACCESSWIRE • 06-28-2023
By ACCESSWIRE ACCESSWIRE • 04-28-2022
By ACCESSWIRE ACCESSWIRE • 03-17-2023
By ACCESSWIRE ACCESSWIRE • 12-02-2022
By ACCESSWIRE • 10-12-2023
By ACCESSWIRE ACCESSWIRE • 05-24-2022
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.